Literature DB >> 27355555

Midostaurin in Advanced Systemic Mastocytosis.

Marie-Olivia Chandesris1, Gandhi Damaj2, Danielle Canioni3, Chantal Brouzes3, Ludovic Lhermitte3, Katia Hanssens4, Laurent Frenzel3, Zoubair Cherquaoui3, Isabelle Durieu5, Stéphane Durupt5, Emmanuel Gyan6, Odille Beyne-Rauzy7, David Launay8, Cyril Faure9, Mohamed Hamidou10, Sophie Besnard11, Momar Diouf12, Aurélie Schiffmann13, Mathilde Niault14, Pierre-Yves Jeandel15, Dana Ranta16, Remi Gressin17, Sylvain Chantepie2, Stéphane Barete18, Patrice Dubreuil4, Philippe Bourget3, Olivier Lortholary3, Olivier Hermine19.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27355555     DOI： 10.1056/NEJMc1515403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

Review 1.  Midostaurin: a magic bullet that blocks mast cell expansion and activation.

Authors:  P Valent; C Akin; K Hartmann; T I George; K Sotlar; B Peter; K V Gleixner; K Blatt; W R Sperr; P W Manley; O Hermine; H C Kluin-Nelemans; M Arock; H-P Horny; A Reiter; J Gotlib
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

2.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Authors:  Georg Greiner; Nadine Witzeneder; Angelika Berger; Klaus Schmetterer; Gregor Eisenwort; Ana-Iris Schiefer; Simone Roos; Theresia Popow-Kraupp; Leonhard Müllauer; Johannes Zuber; Veronika Sexl; Lukas Kenner; Wolfgang R Sperr; Peter Valent; Matthias Mayerhofer; Gregor Hoermann
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

Review 3.  Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Authors:  John H Baird; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 4.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

Review 5.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe
Journal:  Cancer Res       Date:  2017-03-02       Impact factor: 12.701

Review 6.  Target Therapies for Systemic Mastocytosis: An Update.

Authors:  Mariarita Sciumè; Claudio De Magistris; Nicole Galli; Eleonora Ferretti; Giulia Milesi; Pasquale De Roberto; Sonia Fabris; Federica Irene Grifoni
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-11

Review 7.  Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Authors:  Molly M Gallogly; Hillard M Lazarus; Brenda W Cooper
Journal:  Ther Adv Hematol       Date:  2017-08-19

8.  Acute Myeloid Leukemia With Inv(16)(p13q22) Associated With Hidden Systemic Mastocytosis: Case Report and Review of Literature.

Authors:  Feryal Abbas Ibrahim Hilmi; Ahmad Al-Sabbagh; Dina Sameh Soliman; Hesham Al Sabah; Omar Mohammad Ismail; Mohamed Yassin; Halima El-Omri
Journal:  Clin Med Insights Blood Disord       Date:  2017-03-30

9.  Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.

Authors:  Katarina Lyberg; Hani Abdulkadir Ali; Jennine Grootens; Matilda Kjellander; Malin Tirfing; Michel Arock; Hans Hägglund; Gunnar Nilsson; Johanna Ungerstedt
Journal:  Oncotarget       Date:  2017-02-07

Review 10.  Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.

Authors:  Cecilia Monaldi; Sara De Santis; Manuela Mancini; Samantha Bruno; Michele Cavo; Simona Soverini
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-07-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.